NextCell Pharma (NXTCL.ST)

Executive Summary

NextCell Pharma AB is a Swedish biotechnology company specializing in the development of stem cell therapies derived from umbilical cord tissue. The company operates two primary business segments: its proprietary stem cell therapy platform, ProTrans, and a tissue establishment and biobank classified as a healthcare provider. ProTrans, the lead candidate, is being evaluated in clinical trials for autoimmune and inflammatory diseases, with a focus on type 1 diabetes. By leveraging its expertise in cell therapy manufacturing and banking, NextCell aims to address significant unmet medical needs in regenerative medicine. The company is publicly traded on the Nasdaq First North Growth Market under the ticker NXTCL.ST and has a market valuation of approximately 136.6 million USD. With a strong foundation in cell processing and a dedicated pipeline, NextCell is positioned to advance its therapeutic platform while generating revenue from its biobanking services.

Upcoming Catalysts (preview)

• Q3 2026Phase 2b data readout for ProTrans in type 1 diabetes40% success
• Q4 2026Regulatory filing for expanded access or compassionate use in EU50% success
• Q1 2027Partnership or licensing deal for ProTrans in autoimmune indications30% success